A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2004
11/04/2004	US20040219219 Compositions containing alpha-2-adrenergic agonist components
11/04/2004	US20040219218 tablets or capsules of T3 or T4 or their salts in a uniform soft gel matrix that can be taken orally without chewing
11/04/2004	US20040219217 Conjugates of polysaccharide polymers of natural origin
11/04/2004	US20040219214 a synthetic polymer with multiple activated groups and a drug reduce surgical adhesions
11/04/2004	US20040219213 Oral pulsed dose drug delivery system
11/04/2004	US20040219212 Single-daily dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
11/04/2004	US20040219211 a tablet which disintigrates in the mouth, having enterically coated microgranules of a benzimidazole type proton pump inhibitor overcoated with a methacrylic copolymer protective coating, granular antacids, a disintegrating agent, a diluent, and a lubricant; gastrointestinal disorders
11/04/2004	US20040219204 Method of treating angiogenic tissue growth
11/04/2004	US20040219203 Anti-CD74 immunoconjugates and methods
11/04/2004	US20040219202 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety
11/04/2004	US20040219201 Tempamine compositions and methods of use
11/04/2004	US20040219200 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same
11/04/2004	US20040219199 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same
11/04/2004	US20040219194 comprising drug impervious coverings, matrices containing aloe vera extracts, 4-diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenyl-acetate and/or racemic mixtures, release linings, pressure sensitive adhesive and curing agents for the adhesive.
11/04/2004	US20040219181 Sustained release drug delivery devices with coated drug cores
11/04/2004	US20040219175 Thermogelling emulsions for sustained release of bioactive substances
11/04/2004	US20040219158 Cystic fibrosis
11/04/2004	US20040219134 implantation or attachment of an engineered three-dimensional stromal tissue to promote endothelialization and angiogenesis in the heart and related tissues
11/04/2004	US20040219131 Interferon-alpha polypeptides and conjugates
11/04/2004	US20040219120 Composition comprising polymers having a star structure, the polymers, and their use
11/04/2004	US20040219114 Cream for treatment of skin injured by the sun
11/04/2004	US20040219107 The applicator assembly includes a sleeve that encases a swab having a portion that contacts a gelled composition; the sleeve is manually severed to expose the applicator and the composition
11/04/2004	US20040219106 Compounds for use as surfactants
11/04/2004	US20040219101 Human vascular endothelial or epidermal growth factor and radiolabeled human transferrin; multitargeting, antimetastasis
11/04/2004	DE29825080U1 Pharmazeutische Fenofibratzusammensetzung mit erhöhter Bioverfügbarkeit Pharmaceutical fenofibrate with increased bioavailability
11/04/2004	CA2821376A1 Magnetically controllable drug and gene delivery stents
11/04/2004	CA2821214A1 Magnetically controllable drug and gene delivery stents
11/04/2004	CA2523197A1 Peptide vectors
11/04/2004	CA2522891A1 Treatment or prevention of respiratory viral infections with alpha thymosin peptides
11/04/2004	CA2522828A1 Di-glycosil glyceryl compounds for the stabilisation and preservation of biomaterials
11/04/2004	CA2522819A1 Polyvalent protein complex
11/04/2004	CA2522580A1 A medicament for the two-step perioperative therapy of solid tumours
11/04/2004	CA2522364A1 Polymer-conjugated glycosylated neublastin
11/04/2004	CA2522158A1 Devices and apomorphine pharmaceutical compositions for enhancing dosingefficiency
11/04/2004	CA2520881A1 Ligand-coupled initiator polymers and methods of use
11/04/2004	CA2518336A1 Polyethelene glycol link glp-1 compounds
11/03/2004	EP1473300A1 Pharmaceutical composition for the treatment of psoriasis and other skin diseases
11/03/2004	EP1473056A1 An iontophoresis reservoir-electrode and a method for preparing a charged reservoir-electrode unit
11/03/2004	EP1473047A1 Microbial cellulose wound dressing, containing PHMB, for treating chronic wounds
11/03/2004	EP1473031A1 Sucrose ester - C20 to C28 alcohol formulations
11/03/2004	EP1473003A2 Drug delivery device
11/03/2004	EP1472351A2 Amino acid sequences capable of facilitating penetration across a biological barrier
11/03/2004	EP1472290A2 Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof
11/03/2004	EP1472289A1 Stabilization of protein preparations
11/03/2004	EP1472277A1 Fap-activated anti-tumor compounds
11/03/2004	EP1472276A2 Small peptides capable of modulating the function of cd66 (ceacam) family members
11/03/2004	EP1472272A1 Crystalline complexes of fluticasone 2-furoate
11/03/2004	EP1472269A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/03/2004	EP1472267A2 Rna interference mediated inhibition of protein tyrosine phosphatase type iva (prl3) gene expression using short interfering nucleic acid (sina)
11/03/2004	EP1472265A2 Rna interference mediated inhibition of polycomb group protein ezh2 gene expression using short interfering nucleic acid (sina)
11/03/2004	EP1472242A1 Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
11/03/2004	EP1472211A1 Emollients and cosmetic compositions
11/03/2004	EP1471995A1 Encapsulation process and encapsulated compositions
11/03/2004	EP1471944A2 Pharmaceutical composition which improves in vivo gene transfer
11/03/2004	EP1471943A2 Conjugate for treating prokaryotic infections
11/03/2004	EP1471942A1 Immunocytokine-containing lyophilized preparation
11/03/2004	EP1471941A1 Method of treatment of vulval vestibulitis
11/03/2004	EP1471933A1 Albumin-fused anti-angiogenesis peptides
11/03/2004	EP1471932A1 Use of a polypeptide for treatment of pruritus in animals
11/03/2004	EP1471928A1 Hiv inhibiting proteins
11/03/2004	EP1471925A2 Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions
11/03/2004	EP1471919A1 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist
11/03/2004	EP1471900A1 Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor agonist for the treatment of inflammatory and allergic conditions
11/03/2004	EP1471899A1 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias
11/03/2004	EP1471898A1 Lutein/zeaxanthin for glare protection
11/03/2004	EP1471896A1 Formulations for inhalation
11/03/2004	EP1471895A1 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
11/03/2004	EP1471894A1 Cyclodextrines for use as suspension stabilizers in pressure-liquefied propellants
11/03/2004	EP1471892A2 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
11/03/2004	EP1471891A2 Polymer-based compositions for sustained release
11/03/2004	EP1471890A2 Pharmaceutical dosage form for mucosal delivery
11/03/2004	EP1471889A2 Oral pediatric trimethobenzamide formulations and methods
11/03/2004	EP1471888A2 Oral trimethobenzamide formulations and methods
11/03/2004	EP1471887A2 Nanoparticulate compositions having lysozyme as a surface stabilizer
11/03/2004	EP1471886A1 Method for increasing the water-solubility of lipophilic, active substances, production of highly concentrated aqueous compositions of said active substances, corresponding products and their use
11/03/2004	EP1471885A2 Efficient liposomal encapsulation
11/03/2004	EP1471884A1 Pharmaceutical formulation comprising an androstane derivative and a solubilising agent in an aqueous liquid carrier
11/03/2004	EP1471879A1 Topical glycopyrrolate product
11/03/2004	EP1471870A2 Use of lipid conjugates in the treatment of disease
11/03/2004	EP1267842B1 Method for producing a controlled-release tablet using a pore forming agent in the coating
11/03/2004	EP1071464B1 Spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin and a method of making such spray-dried tablettable powders
11/03/2004	EP1071400B1 Drug delivery of proteins from polymeric blends
11/03/2004	EP0888118B1 Enhancement of microbial colonisation of the gastrointestinal tract
11/03/2004	EP0789708B1 Multifunctional molecular complexes for gene transfer to cells
11/03/2004	CN1543476A Methods and compounds for the targeting of protein to exosomes
11/03/2004	CN1543359A Compositions and preparation methods for bioavailable oral aceclofenac dosage forms
11/03/2004	CN1543358A Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
11/03/2004	CN1543357A 5-CNAC as oral delivery agent for parathyroid hormone fragments
11/03/2004	CN1543353A Composition for treatment of articular cartilage damage
11/03/2004	CN1543350A Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier
11/03/2004	CN1543349A Enhanced drug delivery in transdermal systems
11/03/2004	CN1543339A Porous matrix comprising cross-linked particles
11/03/2004	CN1543338A Chitin microparticles and their medical uses
11/03/2004	CN1543337A Expandable gastric retention device
11/03/2004	CN1541712A Fe3O4 magnetofluid and its preparation
11/03/2004	CN1174248C Graphitic nanotube for electrochemiluminescent detection , its composition ,detection agent and detection method thereof
11/03/2004	CN1174037C Gel composition
11/03/2004	CN1173945C 5-thia-omega-substituted phenyl-prostaglandin E derivatives, process for producing same and drugs containing same as active ingredient
11/03/2004	CN1173937C (3S,4S) and (3R,4R)-beta-methyl-gamma-hydroxy-alkyl nitrile and its preparation and use
11/03/2004	CN1173745C Use of chemically modified methioninase in anti-methionine and anti-homocysteine chemotherapy

1 ... 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 ... 1712